Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11190277 | 0.87 | NR1H2 (0.61) | NR1H2CYP3A4TSHRMAPK1ALOX15 | |
| SCHEMBL613358 | 0.86 | CYP3A4 (0.48) | NR1H2CYP3A4TSHRMAPK1ALOX15 | |
| SCHEMBL7869707 | 0.82 | CYP3A4 (0.67) | CYP3A4TSHRMAPK1ALOX15ALDH1A1 | |
| SCHEMBL28246410 | 0.81 | NR1H2 (0.93) | NR1H2CYP3A4TSHRMAPK1ESR2 | |
| SCHEMBL6366825 | 0.80 | MAOA (0.47) | CYP3A4TSHRMAPK1ALOX15ALDH1A1 | |
| SCHEMBL30398364 | 0.80 | MAOA (0.47) | CYP3A4TSHRMAPK1ALOX15ALDH1A1 | |
| SCHEMBL29053002 | 0.78 | MEN1 (0.49) | CYP3A4TSHRMAPK1ALOX15ALDH1A1 | |
| SCHEMBL11630774 | 0.78 | TDP1 (0.56) | CYP3A4TSHRMAPK1ALOX15ALDH1A1 | |
| SCHEMBL29726 | 0.78 | NR1H2 (1.00) | NR1H2CYP3A4TSHRMAPK1ESR2 | |
| SCHEMBL10914949 | 0.78 | NR1H2 (1.00) | NR1H2CYP3A4TSHRMAPK1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875727-B2 | methyl [5(6)-(4-alanylaminophenylthio)-1H-benzimidazol-2yl]carbamate; for treating neovascularization, solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2011-01-25 | — | — | US | disclosed |
| EP-1140078-B1 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-11-23 | — | — | US | disclosed |
| US-7081469-B2 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-07-25 | — | — | US | disclosed |
| US-20040058972-A1 | Benzimidazole vascular damaging agents | DAVIS PETER DAVID (GB) | 2004-03-25 | — | — | US | disclosed |
| US-6645950-B1 | Benzimidazole-2-carbamates; antitumor agents; angiogenesis inhibitors; macular degeneration, diabetic retinopathy, rheumatic arthritis, psoriasis, and atherosclerosis treatment | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2003-11-11 | — | — | US | disclosed |
| EP-1140078-A2 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Ltd (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000041669-A2 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058972-A1 | Benzimidazole vascular damaging agents | FLT1, FLT4, PCNA | NR1H2 2233/4885CYP3A4 1054/4885TSHR 3026/4885 |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | FLT4, PCNA, FLT1 | NR1H2 2234/4885CYP3A4 1148/4885TSHR 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.